Advancing hair loss research
Not an actual patient
clinical trials
The first Phase 3 trials for an oral therapy in nearly 30 years.
Veradermics is currently pursuing three multi-center, randomized, double-blind, placebo-controlled studies evaluating the safety and efficacy of VDPHL01, the potential first oral non-hormonal FDA-approved therapy for pattern hair loss, in both men and women.
Our clinical program includes:
Large, randomized
Phase 3 trials
With aim to study 1500 men and women with pattern hair loss.
Dedicated studies for
both men and women
First ever Phase 3 trial for female pattern hair loss.
Not an actual patient
Rigorous clinical
endpoints
Focused on measuring visible pattern hair loss.